Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Investing Intel. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc. (MRK)’s share was trading at ...

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Major pharmaceutical companies around the world—and increasingly in South Korea—are turning to artificial intelligence (AI) ...

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

The Dow Jones Industrial Average is trading down Tuesday afternoon with shares of Merck and Amgen seeing the biggest declines for the blue-chip average.

Behind losses for shares of Merck and Amgen, the Dow Jones Industrial Average is falling Tuesday afternoon.

Merck broke ground on a $1B, 470K SF biotech facility last month at the Chestnut Run Innovation & Science Park in Wilmington, ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

With only about $1.6 billion in debt in December 2024 compared with $0.3 billion in cash and investments, Waters maintains a financially flexible balance sheet with net leverage around 1 time. Waters ...